SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001564590-22-029142
Filing Date
2022-08-11
Accepted
2022-08-11 16:35:00
Documents
68
Period of Report
2022-06-30

Document Format Files

Seq Description Document Type Size
1 10-Q trvi-10q_20220630.htm   iXBRL 10-Q 3011458
2 EX-31.1 trvi-ex311_9.htm EX-31.1 14010
3 EX-31.2 trvi-ex312_7.htm EX-31.2 13984
4 EX-32.1 trvi-ex321_10.htm EX-32.1 10099
5 EX-32.2 trvi-ex322_8.htm EX-32.2 10062
  Complete submission text file 0001564590-22-029142.txt   9359697

Data Files

Seq Description Document Type Size
6 XBRL TAXONOMY EXTENSION SCHEMA trvi-20220630.xsd EX-101.SCH 53815
7 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE trvi-20220630_cal.xml EX-101.CAL 54275
8 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE trvi-20220630_def.xml EX-101.DEF 180706
9 XBRL TAXONOMY EXTENSION LABEL LINKBASE trvi-20220630_lab.xml EX-101.LAB 440704
10 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE trvi-20220630_pre.xml EX-101.PRE 338623
62 EXTRACTED XBRL INSTANCE DOCUMENT trvi-10q_20220630_htm.xml XML 1613189
Mailing Address 195 CHURCH STREET 14TH FLOOR NEW HAVEN CT 06510
Business Address 195 CHURCH STREET 14TH FLOOR NEW HAVEN CT 06510 203-304-2499
Trevi Therapeutics, Inc. (Filer) CIK: 0001563880 (see all company filings)

IRS No.: 450834299 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-38886 | Film No.: 221156435
SIC: 2834 Pharmaceutical Preparations